ElamipretideMitochondria-targeted peptide medicine
Elamipretide targets mitochondrial biology and has a US accelerated approval for a specific Barth syndrome population. That is a meaningful but narrow development, not validation of broad energy or longevity claims.
What is Elamipretide?
Elamipretide is a mitochondria-targeting peptide. The US product Forzinity received accelerated FDA approval in 2025 for a specified Barth syndrome population, based on a muscle-strength endpoint; this is not a general energy or anti-ageing indication. 1 2
How it works
It interacts with cardiolipin in mitochondrial membranes, a target related to mitochondrial structure and function. A cellular mechanism alone does not establish benefit in unrelated diseases. 2 3
Effects studied
What does the evidence show?
Barth syndrome regulatory review; broader uses require separate evidence
The mitochondrial membrane as a target
Elamipretide is a small peptide studied for interactions with cardiolipin, a lipid important to mitochondrial membrane structure and function. Mitochondria do more than produce energy, but their energy-related role explains much of the interest in this approach.
Why Barth syndrome is a distinct setting
Barth syndrome is a rare genetic disorder involving cardiolipin biology. A treatment directed at this system has a specific rationale here. That does not mean it can correct every cause of fatigue or every disorder in which mitochondria are mentioned.
What the US approval means
The FDA granted accelerated approval to Forzinity in 2025 for improving muscle strength in a defined Barth syndrome population. The label links that decision to improvement in knee-extensor strength, an intermediate clinical endpoint, and notes that continued approval may depend on confirmation of benefit. [1,2]
What the approval leaves unanswered
An endpoint involving measured muscle strength is not interchangeable with improved survival, all aspects of physical function or slowed ageing. Injection-site reactions and hypersensitivity also belong in the treatment discussion. For elamipretide, the progress concerns a specific condition and population, under an approval pathway that requires further confirmation of benefit.
Safety & status
Injection-site reactions and hypersensitivity are relevant safety issues. Product-specific eligibility and monitoring should remain attached to the Barth syndrome treatment context. 2
Country and product status
FDA granted accelerated approval to Forzinity in September 2025 to improve muscle strength in patients with Barth syndrome weighing at least 30 kg; EU and Swiss status not established here.
Frequently asked questions
Does accelerated approval mean every clinical benefit is settled?
No. This pathway uses an intermediate endpoint with further confirmation of clinical benefit required. 1
Does the approval support use for everyday fatigue?
No. The FDA decision concerns a specified Barth syndrome population, not general tiredness. 1
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- FDA · First treatment for Barth syndrome, accelerated approval US regulator · Regulator information checked 27 October 2026; indication-specific, not a review of all jurisdictions.
- DailyMed · Forzinity prescribing information US prescribing information · Regulator information checked 27 October 2026; indication-specific, not a review of all jurisdictions.
- Elamipretide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Elamipretide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.